Summary
Hypertension, hyperlipidaemia and cigarette smoking are major risk factors in coronary heart disease. Since many antihypertensive drugs alter plasma lipid levels it is a subject of current discussion that these agents may increase associated coronary risk and therefore offset the beneficial effects of lowering blood pressure. The purpose of this paper is to review clinical and experimental data in the literature on the influence of antihypertensive drugs on lipid metabolism. The thiazides hydrochlorothiazide and chlorthalidone cause an elevation of plasma triglycerides and very low density lipoprotein (VLDL) but have little effect on total cholesterol, low density lipoprotein (LDL) and high density lipoprotein (HDL). The unspecific beta-blockers, e.g. propranolol, do not affect total cholesterol and LDL but increase total triglycerides and VLDL and decrease HDL. The changes of plasma lipids and lipoproteins caused by cardio-selective beta-blockers, e.g. atenolol and metoprolol, and unspecific beta-blockers with intrinsic sympathomimetic activity (ISA), e.g. oxprenolol and pindolol, appear to be qualitatively similar but less pronounced. The alpha1-blocker prazosin reduces total triglycerides and slightly lowers total cholesterol. The concentration of VLDL plus LDL decreases while HDL may increase. Only very few studies have been reported on the effects of other antihypertensive drugs, e.g. clonidine, hydralazine, on plasma lipids. Several experimental studies reveal that antihypertensive agents exert direct effects on triglyceride and cholesterol metabolism. Although the pathophysiological mechanisms and the significance of the alterations of lipid metabolism induced by antihypertensive drugs are not yet clear, the following guidelines for the clinical use of these agents are recommended: (1) before initiating drug treatment in hypertensive patients, blood lipid levels should be measured to exclude a preexisting hyperlipidaemia, (2) during long-term therapy with antihypertensive agents, lipoprotein fractions should be controlled in order to reconsider the therapeutic regime if major alterations of blood lipid levels are observed.
Similar content being viewed by others
Abbreviations
- VLDL:
-
Very Low Density Lipoprotein
- LDL:
-
Low Density Lipoprotein
- HDL:
-
High Density Lipoprotein
Literatur
Assmann G (1982) Lipidstoffwechsel und Atherosklerose. Schattauer, Stuttgart
Lowenstein J, Nensy A-J (1981) The Biochemical Effects of Antihypertensive Agents and the Impact on Atherosclerosis. J Cardiovasc Pharmacol 3 (Suppl 3):256
Freis ED (1982) Should mild Hypertension be treated? New Engl J Med 307:306
W.H.O./I.S.H. (1982) Mild Hypertension Liaison Committee: Trials of the treatment of mild hypertension. An interim Analysis. Lancet I:149
Multiple Risk Factor Intervention Trial Research Group (1982) Multiple Risk Factor Intervention Trial. JAMA 248:1465
Korcok M (1981) Do antihypertensive drugs increase coronary risk? JAMA 246:2012
Leren P (1982) Bei antihypertensiver Therapie auf Fettstoffwechsel achten. München Med Wschr 3
Havel RJ, Goldstein JL, Brown MS (1980) Lipoprotein and lipid transport. Metabolic control of disease. Bondy PV, Rosenberg LE (Hrsg) 8th edition, WB Saunders, Philadelphia, p 393
Havel RJ (1982) Approach to the patient with hyperlipidemia. Lipid disorders. Havel RJ (Hrsg) The medical clinics of North America 66:319
Nestel PJ, Fidge NH (1981) The physiology of plasma lipoproteins. Lipoproteins, Atherosclerosis and Coronary Heart Disease. Miller NE, Lewis B (Hrsg), Elsevier/North-Holland, Biomedical Press 3
Mahley RW (1982) Atherogenic Hyperlipoproteinemia. Lipid disorders, Havel RJ (Hrsg) The medical clinics of north america 66:375
Zilversmit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60:473
Gianturco SH, Gotto AM Jr, Jackson RL et al. (1978) Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia. J Clin Invest 61:320
Kraemer FB, Chen YDI, Cheung RMC et al. (1981) Binding and degradation of very low density lipoproteins from diabetics by mouse peritoneal macrophages. Circ Res 29:411A
Johnson B, Bye C, Labrooy J (1974) Relation of antihypertensive treatment to plasma lipids and other risk factors in hypertensives. Clin Sci Mol Med 47:9
Gluck Z, Baumgarter G, Wedemann P et al. (1978) Increased ratio between serum β- and α-lipoproteins during diuretic therapy: An adverse effect? Clin Sci Mol Med 55:3255
Grimm RH, Leon AS, Hunninghake RB et al. (1981) Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Ann Intern Med 94:7
Johnson BF et al. (1981) The emerging problem of plasma lipid changes during antihypertensive therapy. J Cardiovasc Pharmacol 3 (Suppl 3):172
Ames RP, Hill P (1978) Raised serum lipid concentrations during diuretic treatment of hypertension: a study of predictive indeces. Clin Sci Mol Med 55:311
Johnson BF, Munro-Faure AD, Slack J (1976) Diuretic-induced hypertriglyceridemia. Lancet I:1019
Herbert PN (1983) Effect of propranolol on blood lipids and lipoproteins in myocardial infarction. Presented at Symposium on beta-blockers and lipid metabolism. Heidelberg, FRG
Joos C, Kewitz H, Reinhold-Kourniati D (1980) Effects of diuretics on plasma lipoproteins in healthy men. Eur J Clin Pharmacol 17:251
Ames RP, Hill P (1976) Elevation of serum lipids levels during therapy of hypertension. Amer J Med 61:748
Helgeland A, Hjermann I, Holme U, Loen P (1978) Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. Amer J Med 64:34
Helgeland A, Hjermann I, Loen P, Holme I (1978) Possible metabolic side effects of beta adrenergic blocking drugs. Brit Med J 1:828
von Brummelen P, Gevers-Lauren JA, van Gent CM (1979) Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL-cholesterol in patients with essential hypertension. Curr Med Res Opin 6:24
Ames RP, Hill P (1981) Antihypertensive therapy and the risk of coronary heart disease. J Cardiovasc Pharmacol 3 (Suppl 3):160
Holzgreve, Schwandt P (1983) Effects of long-term hypertensive therapy with beta blockers and diuretics on serum lipoproteins. Presented at symposium on beta blockers and lipid metabolism, Heidelberg, FRG
Meier A, Schiffl H, Weidemann P, Mordasini R, Riesen W, Bachmann C (1981) β-receptor-blocking agents may reverse or prevent diuretic induced increases in serum low-density lipoprotein cholesterol. Clin Sci 61:437
Ames RP, Hill P (1976) Raised serum-lipids during treatment of hypertension with Chlorthalidone. Lancet I:721
Gluck Z, Weidmann P, Mordasini R. et al. (1980) Increased serum low-density lipoprotein cholesterol in men treated short term with the diuretic chlorthalidone. Metabolism 29:240
Gluck Z et al. (1978) Increased ratio between serum β- and α-lipoproteins during diuretic therapy: an adverse effect? Clin Sci Mol Med 55:325
Schnaper H, Fitz A, Frohlich E et al. (1977) Chlorthalidone and serum cholesterol. Lancet II:295
Gluck Z, Weidmann P, Mordasini R et al. (1979) Einfluß einer Diuretikatherapie auf die Serumlipoproteine: Ein unerwünschter Effekt? Schweiz Med Wschr 109:104
Goldmann AI, Steele BW, Schnaper HW et al. (1980) Serum lipoprotein levels during chlorthalidone therapy. JAMA 244:1691
Falck DK, Schreiner A (1983) The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration. Acta Med Scand 213:27
Leren P et al. (1982) Antihypertensive drugs and blood lipids. The Oslo study. Brit J Clin Pharmacol 13 (Suppl 2):441
Day JL, Simpson N, Metcalfe J, Page RL (1979) Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Brit Med J 1:77
Bielmann P, Leduc G, Davignon J (1980) Beta-blockers and changes in lipoprotein fractions. New Engl J Med 302:298
Leren P et al. (1981) Antihypertensive drugs and blood lipids: The Oslo study. J Cardiovasc Pharmacol 3 (Suppl 3):187
Gemma G, Montanari G, Suppa G et al. (1981) Plasma lipid and lipoprotein changes in hypertensive patients treated with propranolol and prazosin. J Cardiovasc Pharmacol 3 (Suppl 3):207
Shaw J, England JDF, Hua ASP (1978) Beta-blockers and plasma triglycerides. Brit Med J 1:986
Moorjani et al. (1980) VII. Int Symp Dr aff Lip Met 546
Berglung et al. (1976) Acta med Scand 199:499
Leren P, Foss PO, Helgeland A et al. (1980) Effect of propranolol and prazosin on blood lipids. The Oslo study. Lancet II:4
Loyd-Mostyn RH, Lefevre D, Lord PS et al. (1971) The effect of beta-adrenergic blocking agents on serum lipids. Atherosclerosis 14:283
Streja D, Mymin D (1978) Effect of propranolol on HDL-cholesterol concentrations. Brit Med J 2:1495
Miettinen TA et al. (1980) Atherosclerosis 36:249
Berglund G et al. (1981) Lancet I:744
Tanaka N et al. (1976) Effect of chronic administration of propranolol on lipoprotein composition. Metabolism 25:1071
Bauer JH, Brooks CS, Weinstein I et al. (1981) Effects of diuretics and propranolol on plasma lipoprotein's lipids. Clin Pharmacol Ther 30:35
Schauer I, Schauer U, Ruhling K et al. (1980) The effect of propranolol treatment on total cholesterol, HDL cholesterol, triglycerides, postheparin lipolytic activity and lecithin: cholesterol acyltransferase in hypertensive individuals. Artery 8:146
England JDF (1981) Aust NZJ Med 11:36
Lehtonen A, Hietanen E, Marnieni J et al. (1982) Effect of pindolol on serum lipids and lipid metabolizing enzymes. Brit J Clin Pharmacol 13 (Suppl 2):445
Leren P, Foss OP, Helgeland A et al. (1981) Effects of pindolol and hydrochlorothiazide on blood lipids. The Oslo study. Clin Trials 18:254
Pasotti Ch, Capra A, Fiorella G et al. (1982) Effects of pindolol and metoprolol on plasma lipids and lipoproteins. Brit J Clin Pharmacol 13 (Suppl 2):435
Miettinen TA, Vanhauen H, Huttunen JK et al. (1982) HDL cholesterol andβ-adrenoceptor blocking agents in a 5-year multifactorial primary prevention trial. Brit J Clin Pharmacol 13 (Suppl 2):431
Ballantyne D, Ballantyne FC, McMurdo (1981) Effect of slow oxprenolol and a combination of slow oxprenolol and cyclopenthiazide on plasma lipoproteins. Atherosclerosis 39:301
Kjeldsen SE, Eide I, Loen P et al. (1982) The effect on HDL cholesterol of oxprenolol and atenolol. Scand J Clin Lab Invest 42:449
Crisp AJ, Kennedy PGE, Hoffbrand BI et al (1980) Lipids and lipoprotein fraction after cyclopenthiazide and oxprenolol: a double-blind crossover study. Curr Med Res Opin 7:101
England JDF, Senions LA, Gibson JC et al. (1980) The effect of metoprolol and atenolol on plasma high density lipoprotein levels in man. Clin Exp Pharmacol Physiol 7:329
Eliasson K, Lins L-E, Rössner S (1981) Serum lipoprotein changes during atenolol treatment of essential hypertension. Eur J Clin Pharmacol 20:335
Rössner S, Weiner B (1983) Hypertension therapy: Comparison between 50 mg atenolol and 200 mg propranolol daily. (in press)
Waal-Manning HJ (1980) The effect of beta-blockers on plasma lipids. Presented at Symposium on Beta-Blocker Therapy, Atlanta, Georgia
Weiner L, Rössner S (1982) A comparison between 50 mg atenolol and 200 mg metoprolol/day with regard to blood pressure, side effects and serum lipoproteins. Int Soc Hypertension Mexico 440A
Waal-Manning HJ, Simpson FO (1977) Beta blockers and lipid metabolism. Brit Med J 1:705
Tuomilekto J, Nissinen A (1980) Experiences with metoprolol durules, a slow-release formulation in hypertension. J int Med Res 8:44
Waal-Manning HJ (1976) Metabolic effects ofβ-adrenoceptor blockers. Drugs 11:121
Beinart IW, Cramp DG, Pearson RM et al. (1979) The effect of metoprolol on plasma lipids. Postgrad med J 55:709
Nilsson A et al. (1978) Europ J Clin Pharm 13:5
Nilsson A, Hansson BG, Hökfelt B (1977) Betablockers and lipid metabolism. Brit Med J 2:126
Moorjani et al. (1980) VII. Int Symp Dr aff Lip Met, 546
Sirtory (1981) In: Kaplan N: Summary. J Cardiovasc Pharmacol 3 (Suppl 3):261
Velasco M, Silva H, Morillo J et al. (1981) Effect of prazosin on blood lipids and on thyroid function in hypertensive patients. J Cardiovas Pharmacol 3 (Suppl 3):193
Havard CWH, Khokhar AM, Flax JS (1981) Open assessment of the effect of prazosin on plasma lipids. J Cardiovasc Pharmacol 3 (Suppl 3):216
Montanari G, Suppa G, Paralovo A et al. (1981) Plasma lipid and lipoprotein changes in hypertensive patients treated with propranolol and prazosin. Int Soc Hypertension, Italy (abstr)
Kokubu T, Itoh I, Kurita H et al. (1981) Effect of prazosin on serum lipids. J Cardiovasc Pharmacol 3 (Suppl 3):199
Lithell H, Waern U, Vessby B (1981) Effect of prazosin on lipoprotein metabolism in premenopausal hypertensive women. J Cardiovasc Pharmacol 3 (Suppl 3):223
Kirkendall WM, Hammond JJ, Thomas JC et al. (1978) Prazosin and Clonidine for moderately severe hypertension. JAMA 240:2553
Perry HM Jr, Mills EJ (1962) The effect of oral hydralazine on circulating human cholesterol. Amer J Med Sci 243:564
Ghiselli G, Bernini F, Nursanti R et al. (1981) Effect of L-Propranolol on the binding, internalization and degradation of 125I-low density lipoproteins by human skin fibroblasts. Biochem Biophys Res Comm 103:1060
Stout RW et al. (1983) Dibutyryl cyclicAMP inhibits LDL binding in cultured fibroblasts and arterial smooth muscle cells. Atherosclerosis 46:13
Efendić S, Östman J (1970) Catecholamines and metabolism of human adipose tissue. Acta med Scand 187:493
Ellis S (1980) Effects on the metabolism. Adrenergic Activators and Inhibitors part I (Szekeres EL Hrsg) Handbook of Exp Pharmacol, Vol 54, I, Springer, New York, p 334
Lafontain M, Berlan M (1980) Evidence for theα-2 nature of theα-adrenergic receptor inhibitor in lipolysis in human fat cells. Eur J Pharmacol 66:87
Kather H, Simon B (1981) Adrenoceptor of the alpha2-subtype mediating inhibition of the human fat cell adenylate cyclase. Eur J Clin Invest 11:111
Wright EE, Simpson ER (1981) Inhibition of the lipolytic action ofβ-adrenergic agonists in human adipocytes byα-adrenergic agonists. J Lipid Res 22:1265
Burns TW, Laugley PE, Terry BE, Bylung DB, Forte LR (1982) Alpha-adrenergic activation inhibits foskolin-stimulated adenylate cyclase activity and lipolysis in human adipocytes. Life Sci 31:815
Kawamura M, Jensen DF, Wancewicz EV, Joy LL, Khoo JC, Steinberg D (1981) Hormone-sensitive lipase in differentiated 3T3-L1 cells and its activation by cyclic AMP-dependent protein-kinase. Proc Nat Acad Sci USA 78:732
Krone W, Müller-Wieland D, Wilke A, Greten H (1982) Effects ofα- andβ-adrenergic receptor stimulation on sterol synthesis in human lymphocytes. Ateriosclerosis 2:413A
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krone, W., Müller-Wieland, D. & Greten, H. Antihypertensive Therapie und Fettstoffwechsel. Klin Wochenschr 62, 193–202 (1984). https://doi.org/10.1007/BF01721044
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01721044